Reducing Injuries From Medication-Related Falls Using Computerized Alerts for High Risk Patients

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2013 by McGill University
Sponsor:
Collaborator:
Canadian Patient Safety Institute
Information provided by (Responsible Party):
Robyn Tamblyn, McGill University
ClinicalTrials.gov Identifier:
NCT00818285
First received: January 5, 2009
Last updated: April 25, 2013
Last verified: April 2013
  Purpose

Drug-related illness accounts for 5% to 23% of hospital admissions, and is now claimed to be the sixth leading cause of mortality. Older adults are at higher risk of adverse drug-related events, and medication-related fall injuries are the most common adverse event that could be potentially prevented. There are 1.2 million falls per year among Canadian elderly, at a cost of $2.4 billion in health care services, and substantial risk of loss of independence.

The overall purpose of this research program is to reduce medication-related fall injuries by using computerized electronic prescribing and drug management systems to identify high risk patients and provide physicians with patient-specific recommendations for modifying psychotropic medication use to reduce this risk.


Condition Intervention
Fall Related Injury Risk
Device: CDS for psychotropic drug management

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Reducing Injuries From Medication-Related Falls by Generating Targeted Computerized Alerts for High Risk Patients Within an Electronic Prescribing System

Further study details as provided by McGill University:

Primary Outcome Measures:
  • rate of potentially inappropriate psychotropic medication [ Time Frame: September 2008-July 2010 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Fall-related injury risk, fall related injuries, and hospitalizations. [ Time Frame: September 2008 - December 2011 ] [ Designated as safety issue: No ]

Estimated Enrollment: 4800
Study Start Date: September 2008
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: 1
Physicians in this arm will be using the standard electronic prescription interface.
Experimental: 2
In addition to the standard electronic prescription module, physicians in this arm will receive targeted drugs alert and decision support for psychotropic drug management
Device: CDS for psychotropic drug management
Computerized decision support (CDS) for patients with available supplies of psychotropic medications. The decision support will consist of a screen displaying to the physician the patient's current risk of falling as well as what their risk could be lowered to with modifications to medications.

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   65 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Physicians are eligible for inclusion if they are general practitioners or family physicians in full-time (≥ 4 days/week), fee-for-service practice in Quebec-patients where the study physician has written or dispensed psychotropic medications

Exclusion Criteria:

  • under 65 years old
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00818285

Contacts
Contact: Robyn Tamblyn, PhD 514-934-1934 ext 32999 robyn.tamblyn@mcgill.ca

Locations
Canada, Quebec
McGill University Recruiting
Montreal, Quebec, Canada
Contact: Robyn Tamblyn, PhD    514-934-1934 ext 32999    robyn.tamblyn@mcgill.ca   
Sponsors and Collaborators
McGill University
Canadian Patient Safety Institute
Investigators
Principal Investigator: Robyn M Tamblyn, PhD McGill University
  More Information

No publications provided by McGill University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Robyn Tamblyn, Professor, McGill University
ClinicalTrials.gov Identifier: NCT00818285     History of Changes
Other Study ID Numbers: RFA06-1035-QC
Study First Received: January 5, 2009
Last Updated: April 25, 2013
Health Authority: Canada: Ethics Review Committee

Additional relevant MeSH terms:
Psychotropic Drugs
Central Nervous System Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 22, 2014